In Coding
Oct 15th, 2010
The U.S. Food and Drug Administration (FDA) has added information to the product label for GlaxoSmithKline’s rotavirus vaccine, which is marketed as Rotarix, after an interim analysis of a postmarketing study in Mexico indicated an increased risk of intussusception in the 31 days after the first dose of the vaccine. MayoClinic.com defines intussusception as a serious ...
May 28th, 2010
The U.S. Food and Drug Administration (FDA) revised its recommendations for rotavirus vaccines on May 14 after determining that it is appropriate for clinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq. After the FDA learned that components of an extraneous virus (PCV1) were present in ...